Sunitinib treatment for refractory malignant pheochromocytoma

Neuroendocrinology Letters

Volumn 33, Issue 3, 2012, Pages 260-264

  Nemoto, Kaoru ^a   Miura, Takafumi ^a   Shioji, Go ^a   Tsuboi, Narumi ^a  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Malignant pheochromocytoma; Molecular target therapy; Partial response; Sunitinib; Tumor lysis syndrome; Tyrosine kinase inhibitor

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANGIOTENSIN RECEPTOR ANTAGONIST; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXAZOSIN MESYLATE; IFOSFAMIDE; SOMATOSTATIN DERIVATIVE; SUNITINIB; VINCRISTINE;

ADRENAL CORTEX TUMOR; ADRENAL PHEOCHROMOCYTOMA; ADRENALECTOMY; ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DOPAMINE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LABORATORY TEST; LIVER TUMOR; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NORADRENALIN BLOOD LEVEL; PHEOCHROMOCYTOMA; SIDE EFFECT; SYNCOPE; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR LYSIS SYNDROME; TUMOR RECURRENCE;

EID: 84862222616     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Adjalle R, Plouin PF, Pacak K, Lehnert H (2009). Treatment of malignant pheochromocytoma. Horm Metab Res. 41: 687-696.
2. Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, et al (2010). Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg. 34: 3022-3028.
3. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al (2011). Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol and Metab. 96: 717-725.
4. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007). The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr-Relat Cancer 14: 569-585. (Pubitemid 350074048)
5. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008). Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 26: 2767-2778.
6. Feng F, Zhu Y, Wang X, Wu Y, Zhou W, Jin X, et al (2011). Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol. 185: 1583-1590.
7. Gedik GK, Hoefnagel CA, Bais E, Olmos RA (2008). 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35: 725-733.
8. Gemici C (2006). Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol) 18: 773-780.
9. Grogan RH, Mitmaker EJ, Duh QY (2011). Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 18: 104-112.
10. Harari A, Inabnet WB, 3rd (2011). Malignant pheochromocytoma: a review. Am J Surg. 201: 700-708.
11. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al (2008). Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113: 2020-2028.
12. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, et al (2009). Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol and Metab. 94: 386-391.
13. Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S, et al (2010). A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med. 49: 991-994.
14. Kloppel G (2011). Classification and pathology of gastroentero-pancreatic neuroendocrine neoplasms. Endocr-Relat Cancer 18 Suppl 1: S1-S16.
15. Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B (2010). Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs 28: 690-693.
16. Morikawa T, Suzuki M, Unno M, Endo K, Katayose Y, Matsuno S (2001). Malignant pheochromocytoma with hepatic metastasis diagnosed 10 years after a resection of the primary incidentaloma adrenal lesion: report of a case. Surg Today 31: 80-84. (Pubitemid 32200350)
17. Mughal TI, Ejaz AA, Foringer JR, Coiffier B (2010). An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 36: 164-176.
18. Nicholaou T, Wong R, Davis ID (2007). Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 369: 1923-1924. (Pubitemid 46874569)
19. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, et al (2009). Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol and Metab. 94: 2850-2856.
20. Oberg K, Castellano D (2011). Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 30 Suppl 1: 3-7.
21. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al (2007). Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 3: 92-102. (Pubitemid 46146962)
22. Park J, Song C, Park M, Yoo S, Park SJ, Hong S, et al (2011). Predictive characteristics of malignant pheochromocytoma. Korean J Urol. 52: 241-246.
23. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, et al (2009). Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol. 39: 327-331.
24. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS, et al (2003). Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956-962.
25. Saylor PJ, Reid TR (2007). Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. 25: 3544-3546. (Pubitemid 47310894)
26. Tanaka S, Ito T, Tomoda J, Higashi T, Yamada G, Tsuji T (1993). Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Intern Med. 32: 789-794.
27. Thompson LD (2002). Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Ame J Surg Pathol. 26: 551-566.
28. Ye L, Santarpia L, Gagel RF (2010). The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 31: 578-599.
29. Zukauskaite R, Hjorthgau K, Poulsen PL, Baerentzen S, Ladekarl M (2011). Malignant pheochromocytoma and paraganglioma: three cases illustrating the use ofmolecular targeted diagnostics and therapy and possible role of new drugs. Acta Oncol. 50: 1255-1259.